LONDON (Alliance News) - Venn Life Sciences Holdings PLC on Friday said it has collaborated with Carrick Therapeutics Ltd to develop innovative cancer treatments.
The drug development company said Carrick is building a portfolio of first-in-class treatments that target multiple mechanisms of the most aggressive forms of cancer.
Carrick has built a network of partners and collaborators to progress its technology portfolio and Venn will join this network as a provider of early development and clinical research capabilities.
"By linking a network of clinicians and scientists in internationally leading research institutes and hospitals, we will use our multi-asset portfolio to drive the development of these ground-breaking cancer therapies from laboratory to clinic," explained Carrick Chief Executive Elaine Sullivan.
"At Venn we have built a suite of capabilities designed to address all of the development requirements of this model and are delighted to partner with Carrick in the development of their first in class treatments," added Venn Life Chief Executive Tony Richardson.
Venn shares were trading 1.7% lower on Friday at 1.77 pence each.
